LBM-415

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525430

CAS#: 478913-91-6

Description: LBM-415 is the first member of the peptide deformylase (PDF) inhibitor class. It is being developed for clinical trials as a parenteral and oral agent for treatment of community-acquired respiratory tract disease and serious infections caused by antimicrobial-resistant gram-positive cocci.

Chemical Structure

img
LBM-415
CAS# 478913-91-6
Instruction

Theoretical Analysis

MedKoo Cat#: 525430
Name: LBM-415
CAS#: 478913-91-6
Chemical Formula: C18H25FN4O5
Exact Mass: 396.18
Molecular Weight: 396.410
Elemental Analysis: C, 54.54; H, 6.36; F, 4.79; N, 14.13; O, 20.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LBM-415; LBM 415; LBM415; NVP-PDF-713.

IUPAC/Chemical Name: (2S)-1-((2R)-2-((Formylhydroxyamino)methyl)hexanoyl)pyrrolidine-2-carboxylic acid N-(5-fluoro-1-oxopyridin-2-yl)amide

InChi Key: LYPFVIYNUQCDPM-HIFRSBDPSA-N

InChi Code: InChI=1S/C18H25FN4O5/c1-2-3-5-13(10-21(27)12-24)18(26)22-9-4-6-15(22)17(25)20-16-8-7-14(19)11-23(16)28/h7-8,11-13,15,27H,2-6,9-10H2,1H3,(H,20,25)/t13-,15+/m1/s1

SMILES Code: O=C([C@H]1N(C([C@@H](CN(C=O)O)CCCC)=O)CCC1)NC2=CC=C(F)C=[N+]2[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 396.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sangshetti JN, Khan FA, Shinde DB. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. Review. PubMed PMID: 25174923.

2: Yu L, Zhou W, Wang Z. Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1541-4. doi: 10.1016/j.bmcl.2010.12.097. Epub 2010 Dec 24. PubMed PMID: 21288715.

3: Wang Z, Zhou W. Synthesis and in vitro antibacterial activity of (2S)-N-(substitutedphenyl)-1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-2-p yrrolidinecarboxamides as potential peptide deformylase inhibitors. Chem Biol Drug Des. 2009 Jan;73(1):142-6. doi: 10.1111/j.1747-0285.2008.00753.x. PubMed PMID: 19152643.

4: Guay DR. Drug forecast - the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag. 2007 Aug;3(4):513-25. PubMed PMID: 18472972; PubMed Central PMCID: PMC2374925.

5: Wang W, White R, Yuan Z. Proteomic study of peptide deformylase inhibition in

Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob Agents Chemother.

2006 May;50(5):1656-63. PubMed PMID: 16641432; PubMed Central PMCID: PMC1472206.

6: Butler MS, Buss AD. Natural products--the future scaffolds for novel antibiotics? Biochem Pharmacol. 2006 Mar 30;71(7):919-29. Epub 2005 Nov 14. Review. PubMed PMID: 16289393.

7: Waites KB, Reddy NB, Crabb DM, Duffy LB. Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. PubMed PMID: 15917568; PubMed Central PMCID: PMC1140545.

8: Molecule of the month. LBM-415. Drug News Perspect. 2005 Jan-Feb;18(1):46. PubMed PMID: 15753974.